扶桑薬品工業 raised its earnings forecast for the April-September 2026 period, forecasting revenue of ¥32.3 billion, operating profit of ¥1.7 billion, and net income of ¥1 billion. These represent increases of ¥800 million, ¥900 million, and ¥500 million, respectively, from the previous forecast.
扶桑薬品工業 raised its earnings forecast for the April-September 2026 period. The new forecast calls for revenue of ¥32.3 billion, operating profit of ¥1.7 billion, and net income of ¥1 billion, all higher than the previous forecast. The figures are based on the company’s latest earnings outlook.
Revenue was revised upward by ¥800 million from the previous forecast, operating profit by ¥900 million, and net income by ¥500 million. The improvement in these metrics was reported to reflect the contribution of promotional activities.
The upward revision was reported to have been driven by the contribution of sales promotion activities and other factors. No additional details on specific figures or timing were provided in the article, but promotional measures during the period were believed to have contributed to earnings.
扶桑薬品工業 is a company focused on pharmaceutical manufacturing, and the revision represents an improvement in its earnings outlook for the first half of fiscal 2026. Further information is awaited.